TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02896179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training group+VR
Description: The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GEO
Description: The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GE-O System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles
Study: NCT01849484

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation according to indication with hippocampal sparing
Description: Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation according to indication without hippocampal protection
Description: Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
Study: NCT00683566

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrostimulation
Description: Stimulate STN (at 0, 5, 10, 15, 20, 25, 30, 40, 70 and 130 Hz) in chronically implanted patients at rest and during simple and complex motor tasks
Study: NCT03707925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cone-Beam Computed Tomography
Description: Undergo CBCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo standard resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Ablation
Description: Undergo bronchoscopic laser ablation
Study: NCT00797498

Intervention type: OTHER
Intervention: Xerostomia questionnaire
Description: All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
Study: NCT02138721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy (RP)
Description: Radical Prostatectomy with extended Pelvic Lymph Node Dissection within 8 weeks after inclusion.
Study: NCT02750098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose measurement
Description: 1. Elective cataract surgery~2. Blood glucose measurement - glucometer~3. Aqueous humor glucose measurement - at beginning of cataract surgery - glucometer~4. Perioperative Hemoglobin A1c level - blood laboratory test
Study: NCT00662779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arformoterol
Description: 15 mcg arformoterol nebulizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Description: Formoterol 12 mcg/inhalation, dry powder inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo dry powder capsules ( lactose) and placebo normal saline for nebulization
Study: NCT02536573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radlink Surgical Positioning Software
Study: NCT04896138

Intervention type: OTHER
Intervention: Interstitial Lung Disease
Description: Not applicable - this is not an interventional trial
Study: NCT03553654

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: low dose CT
Description: CT-based protocol for detection of anthracycline-induced myocardial dysfunction at early stages
Study: NCT01117857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: One-week placebo lead-in, followed by Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg per day for the remaining 7 weeks of the study.
Study: NCT02499081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Study: NCT03773822

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydrocortisone + Flucortac
Description: Low dose steroids

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00321659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic
Description: 3x/week of walking and cycling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: 3x/week of resistance training activities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination
Description: 3x/week of aerobic and strength training activities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FSHC
Description: Biweekly group education group meetings
Study: NCT00364156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Patch Treatment
Description: 8-weeks of nicotine patch + 16-weeks of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 24-weeks of nicotine patch
Description: 24-weeks of 21mg nicotine patch
Study: NCT03450720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2737 single dose
Description: GLPG2737 oral suspension, single dose
Study: NCT03679806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Halliwick
Description: The exercise program was progressed by increasing the speed and the range of motion of the movements. Patients were asked not to accelerate the exercise and to focus on their alignment. Mental adjustment, sagittal rotation, transverse rotation, and combined rotation controls, balances in stillness steps of the Halliwick concept were included.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Plyometric Exercises
Description: The APE programme was progressed by increasing speed and the range of motion of the movements. Patients were carefully informed not to deform the exercise just to emulate the speed. The three phases of each exercise; eccentric (or loading) phase, the amortization phase, and the concentric (or unloading) phase explained thoroughly at the beginning of every exercise.
Study: NCT01118689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 administered orally once daily for 28 days
Study: NCT04452487

Intervention type: BEHAVIORAL
Intervention: decisions of limitations and stop processing
Description: Compliance of the modalities of decisions of limitations and stop processing

Intervention type: BEHAVIORAL
Intervention: decisions of limitations and stop processing
Description: Compliance of the modalities of decisions of limitations and stop processing

Intervention type: BEHAVIORAL
Intervention: decisions of limitations and stop processing
Description: Compliance of the modalities of decisions of limitations and stop processing
Study: NCT02910479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-Celsius thermometer
Description: comparison of temperature between e-celsius and thermometer, rectal thermometer, esophageal thermometer, vital sense capsule thermometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectal thermometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal thermometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vital sense capsule thermometer
Study: NCT04641182

Intervention type: OTHER
Intervention: Prone position
Description: Prone position as indicated by the treating physician as specified in the institutional protocol
Study: NCT03856788

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 40 mL sterile normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 40 mL 0.25% bupivacaine
Study: NCT03561805

Intervention type: DEVICE
Group type: OTHER
Intervention: ECG monitoring
Description: Prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure
Study: NCT00106704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Sitagliptin
Description: sitagliptin 10 mg tablet, once daily for 54 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo oral tablet once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Pioglitazone
Description: Pioglitazone 30 mg tablet once daily for 30 weeks
Study: NCT01403532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional intervention for HH using HCG and FSH
Description: Human chorionic gonadotropin(HCG),2000U,im,2 times/week, one year and a half; Follicle stimulating hormone(FSH),75U, im, 3 times/week, one year;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential intervention for HH using HCG and FSH
Description: Human chorionic gonadotropin,2000U,im, 2 times/week, one and half a year Follicle stimulating hormone,75U,im,3 times/week, every other three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential intervention for HH using HCG and FSH plus zinc
Description: Human chorionic gonadotropin,2000U,im,2 times/week, one year and a half Follicle stimulating hormone,75U, im, 3 times/week, every other three months Zinc gluconate 20mg,P.O, twice daily
Study: NCT03516630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone 20 mg
Description: Oral drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone 60 mg
Description: Oral drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone 140 mg
Description: Oral drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral drops
Study: NCT02749656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Desoximetasone cream (Topoxy®)
Description: apply on the scalp psoriasis lesion twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Desoximetasone cream (Topicorte®)
Description: apply on the scalp psoriasis lesion twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: apply on the scalp psoriasis lesion twice a day
Study: NCT01298518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04620110
Description: 5 mg of PF-04620110 given once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04620110
Description: 2.5 mg of PF-04620110 given twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo giving for 4 weeks
Study: NCT02089841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.
Study: NCT03877432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermatome stimulation
Description: Dermatome (S2-S4) stimulation is aimed at improving the function of bladder storage and bladder capacity. A total of 8 serial cystometrograms will be performed: 2 control fills, followed by 4 fills with stimulation, followed by 2 control fills. The minimum (or threshold) stimulation amplitude (T) necessary to elicit the genito-anal reflex was first determined for each subject. Subsequently, each subject received a randomized sequence of cystometric fill trials with and without continuous dermatome stimulation. The dermatome stimulation was randomly stimulated at stimulation amplitudes of 1, 2, 3, and 4 T.
Study: NCT01110811

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transoral Incisionless Fundoplication (TIF)
Description: The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degress around the esophagus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transoral Incisionless Fundoplication (TIF)
Description: The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degress around the esophagus.
Study: NCT02921204

Intervention type: OTHER
Intervention: Vitamin D status
Description: There is no intervention in this study
Study: NCT04525482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early goal-directed sedation programs
Description: A. Provide sedation at the beginning of the titration of dextrometomidine; b. Optimize sedation when dextrometomidine is used alone and at a maximum dose not sufficient to provide comfort and safety to the patient and to achieve a level of sedation at any time specified by the treating physician. C. Provides immediate recovery and sedation, and can control sudden agitation at any time
Study: NCT03456531

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency
Description: The patient will have pulsed radiofrequency to suprascapular nerve for 6 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NSAIDs ibubrofen,Aspirin
Description: medical treatment as NSAIDs ibubrofen,Aspirin
Study: NCT03196232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02882932

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Super Oxidized Solution in group I
Description: Two groups were made as group I and group II. Peritoneal Lavage was given with SOS and normal saline in group I. in group II only normal saline wash was given.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Super Oxidized Solution in group I
Description: Two groups were made as group I and group II. Peritoneal Lavage was given with SOS and normal saline in group I. in group II only normal saline wash was given.
Study: NCT03543696

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single Dose Radiotherapy (SDRT)
Study: NCT02927418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength & Conditioning

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study: NCT00506545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 619734
Description: SCH 619734 50-mg capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dose 1
Description: Matching placebo capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
Study: NCT01791803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypnotherapy
Description: One 90 minute session within 2 weeks of hospital discharge

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypnotherapy
Description: One 90 minute session within 2 weeks of hospital discharge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: free one month supply after hospital discharge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: free one month supply after hospital discharge
Study: NCT03298685

Intervention type: OTHER
Intervention: semi structured interviews for all adolescents and their parent
Description: Before and after transition, individual semi structured interviews will be recorded by one person in the same way in all CF center. And every interview will be transcribed by an other person
Study: NCT02778243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: steroids concentrations determination

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: steroids concentrations determination
Study: NCT04369989

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01980654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: All subjects will receive 560 mg of Ibrutinib orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: All subjects will receive 560 mg of Ibrutinib orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: All subjects will receive rituximab 375 mg/m2 intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: All subjects will receive rituximab 375 mg/m2 intravenously
Study: NCT04109196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy is an evidence-based treatment for PTSD that will be delivered intensively twice per day over the course of five days.
Study: NCT00186862

Intervention type: DRUG
Group type: OTHER
Intervention: Interleukin-2
Description: A genetically modified (retroviral) allogeneic tumor vaccine coupled with the human interleukin-2. Patients were treated with 4 injections of these gene-modified tumor cells. The first two were given at weeks 1 and 2. Patients then had a 2 week rest and the remaining 2 injections were given at weeks 4 and 5. A complete evaluation for evidence of toxicity and response were performed at week 8.~At this week 8 evaluation, if there was no excessive toxicity, progressive disease requiring therapy, and if more transduced cells are available, patients had the option to receive 4 additional injections. These additional injections were separated by 1 month at the higher of the two dosage levels originally received.
Study: NCT03774160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Generacion Actual
Description: See description in arm description.
Study: NCT03635333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine level (6 or 18 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine level (6 or 18 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine level (6 or 18 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine level (6 or 18 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine level (6 or 18 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine level (6 or 18 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavor
Description: Flavor of e-juice (tobacco, menthol, strawberry)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavor
Description: Flavor of e-juice (tobacco, menthol, strawberry)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavor
Description: Flavor of e-juice (tobacco, menthol, strawberry)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavor
Description: Flavor of e-juice (tobacco, menthol, strawberry)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavor
Description: Flavor of e-juice (tobacco, menthol, strawberry)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavor
Description: Flavor of e-juice (tobacco, menthol, strawberry)
Study: NCT01969591

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fast-track surgery
Description: Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional postoperative surgery
Description: Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
Study: NCT00604279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (R092670)
Description: Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone LAI intramuscular at a dose of 25 mg on Day 8 and Day 22; flexible dose of either 25 or 37.5 mg on Day 36 with same dose on Day 50; and either 25, 37.5, or 50 mg on Day 64 with same dose on Day 78; along with oral risperidone 2 mg tablet on Day 1, flexible doses (1-6 mg/day) for first 28 days; and 1-2 mg/day during Day 36-57 and Day 64-85 if the dose of risperidone LAI was increased on Day 36 and Day 64.
Study: NCT02672215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Start to stand
Description: web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: generic advice
Description: general, non-tailored web-based generic advice with tips
Study: NCT01602523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/formoterol
Description: Budesonide/formoterol Spray inhaler 160/4.5 mcg daily 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhaler once daily 28 days
Study: NCT04234425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Yoga
Description: Trauma-Informed Yoga practice held within a high school weight training class
Study: NCT01072877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol injectable foam (PEM)
Description: Injection of Polidocanol injectable foam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol injectable foam (PEM)
Description: Injection of Polidocanol injectable foam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol injectable foam (PEM)
Description: Injection of Polidocanol injectable foam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol injectable foam (PEM)
Description: Injection of Polidocanol injectable foam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Description: Placebo vehicle
Study: NCT00003600

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epoetin alfa

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo